Karius
Karius57About
What does Karius do?
Karius provides advanced infectious disease diagnostics by leveraging clinical metagenomics and AI to detect microbial cell-free DNA. Their core products, Karius Spectrum™ and Karius Focus™ | BAL, offer rapid and comprehensive pathogen detection for systemic and lung infections, respectively. Karius serves patients and healthcare providers by enabling clear and timely diagnoses for difficult-to-diagnose infections.
What is Karius's revenue?
StartupHub estimates Karius's annual revenue at $37.9M (range $20.4M to $58.3M, 64% confidence), based on comparable companies in the sector.
What is Karius's valuation?
StartupHub estimates Karius's effective valuation at $1.3B (range $787.5M to $1.9B, 14% confidence), based on comparable companies in the sector.
How much funding has Karius raised?
Karius has raised a total of $315M in funding. The most recent round on record is Series C.
When was Karius founded?
Karius was founded in 2014.
What industry does Karius operate in?
Karius operates in Life Sciences, Biotech, Genomics, Blood.
How many employees does Karius have?
Karius has approximately 214 people on record.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Biotalent is a platform that streamlines biotech hiring by connecting qualified candidates with job opportunities and providing hiring teams with tools for efficient candidate review.
AI-powered platform accelerating biological research and drug discovery.
A healthcare and life sciences consulting firm leveraging AI and data analytics for strategic solutions.
Empowering Life Science Entrepreneurs for Innovative Healthcare Solutions.
An entrant is a company tagged Life Sciences whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.